Amgen’s Tepezza is facing a broader thyroid eye disease treatment landscape after Viridian Therapeutics’ Lumvoa became another approved option, shifting attention toward how physicians may weigh evidence, safety, treatment burden and patient fit. Dr. Raymond Douglas, MD, PhD, who served as principal investigator in the international Tepezza trials that supported its United States Food and
Yarrow Bioscience starts Phase 2 dosing of YB-101 after its VYNE merger, testing a targeted approach to Graves’ disease and thyroid eye disease.
See how Lumvoa’s FDA approval could reshape thyroid eye disease treatment, challenge Tepezza and test Viridian’s launch strategy.
Find out how Minghui Pharmaceutical’s MHB018A could reshape thyroid eye disease treatment as Phase III trials test its promise.
Bispecific antibodies are moving beyond oncology. Innovent’s autoimmune pipeline now faces the harder test of clinical durability.
Viridian has TED trial wins, but market entry needs capital. See why its $350m raise matters before commercialization.